Use of an extract of animal, plant or microorganism-produced origin comprising docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal. The medicament is administered to a patient who is concomitantly receiving a highly active anti-retroviral therapy (HAART). The treatment is effective and overcomes the disadvantages of current lipodystrophy treatments in HIV-infected patients.
